A Phase II, Double-Blind, Placebo-Controlled, Randomised Study to Assess the Efficacy and Safety of Docetaxel (Taxotere)/Prednisolone/ZD6474 vs Docetaxel/Prednisolone/Placebo in Patients With Hormone Refractory Prostrate Cancer (HRPC).

Next Previous
Trial Profile

A Phase II, Double-Blind, Placebo-Controlled, Randomised Study to Assess the Efficacy and Safety of Docetaxel (Taxotere)/Prednisolone/ZD6474 vs Docetaxel/Prednisolone/Placebo in Patients With Hormone Refractory Prostrate Cancer (HRPC).

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Vandetanib (Primary) ; Docetaxel; Prednisolone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 21 Nov 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004144).
    • 14 Apr 2009 Actual end date changed from Nov 2006 to Sep 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top